The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogilvie, P.
Right arrow Articles by Thelen, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogilvie, P.
Right arrow Articles by Thelen, M.
The Journal of Immunology, 2004, 172: 6715-6722.
Copyright © 2004 by The American Association of Immunologists

Unusual Chemokine Receptor Antagonism Involving a Mitogen-Activated Protein Kinase Pathway1

Patricia Ogilvie2,*, Sylvia Thelen2,*, Barbara Moepps{dagger}, Peter Gierschik{dagger}, Ana Claudia da Silva Campos*, Marco Baggiolini* and Marcus Thelen3,*

* Institute for Research in Biomedicine, Bellinzona, Switzerland; and {dagger} Department of Pharmacology and Toxicology, University of Ulm, Ulm, Germany

Antagonism of chemokines on chemokine receptors constitutes a new regulatory principle in inflammation. Eotaxin (CCL11), an agonist for CCR3 and an attractant of eosinophils, basophils, and Th2 lymphocytes, was shown to act as an antagonist for CCR2, which is widely expressed on leukocytes and is essential for inflammatory responses. In this report we provide direct evidence for a novel mechanism how chemokine receptor function can be arrested by endogenous ligands. We show that binding of eotaxin to CCR2 stimulates the mitogen-activated protein kinases extracellular signal-regulated kinase 1/2 (ERK1/2). Activation of the mitogen-activated protein kinase kinase 1/2-ERK pathway is indispensable for eotaxin-mediated attenuation of CCR2 function, as inhibition of ERK phosphorylation abolishes the arresting effect. ERK is also activated by CCR2 agonists, e.g., monocyte chemoattractant protein-1 (CCL2). However, the involved pathways are different, although in either case coupling of CCR2 to pertussis toxin-sensitive heterotrimeric G proteins is necessary. The results are in agreement with the view that CCR2 could assume different activation states depending on the ligand it encounters. With respect to actin polymerization and calcium mobilization, the different activation states lead to agonistic and antagonistic responses. It is conceivable that the intracellular signal transduction pathway that is activated by eotaxin could cause an attenuation of proinflammatory responses mediated by CCR2.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
S. Basu, V. R. Jala, S. Mathis, S. T. Rajagopal, A. Del Prete, P. Maturu, J. O. Trent, and B. Haribabu
Critical Role for Polar Residues in Coupling Leukotriene B4 Binding to Signal Transduction in BLT1
J. Biol. Chem., March 30, 2007; 282(13): 10005 - 10017.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. L. Simoes and I. M. Fierro
Involvement of the Rho-Kinase/Myosin Light Chain Kinase Pathway on Human Monocyte Chemotaxis Induced by ATL-1, an Aspirin-Triggered Lipoxin A4 Synthetic Analog
J. Immunol., August 1, 2005; 175(3): 1843 - 1850.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. C. Fulkerson, H. Zhu, D. A. Williams, N. Zimmermann, and M. E. Rothenberg
CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism
Blood, July 15, 2005; 106(2): 436 - 443.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.